NY-AQARA
3.11.2022 09:01:35 CET | Business Wire | Press release
Aqara, a leading provider for smart home products, shares its latest plan of Matter support and integration for its existing and new devices. Aqara is fully committed to supporting Matter, and the Company has been working with the Connectivity Standards Alliance (CSA) and key stakeholders such as Apple, Google and Samsung on early testing programs to ensure a smooth transition towards the new standard. Aqara users will first gain access to Matter in December 2022 via the Aqara Hub M2 through an OTA (over-the-air) update, which will allow existing Aqara Zigbee devices to become compatible with Matter.
Other Aqara hubs, including the Hub M1S/M1S Gen 2, Hub E1, Camera Hub G3, and Camera Hub G2H Pro, will also receive similar OTA updates in the following months so that more Aqara users will be able to enjoy the benefits of Matter. The software updates are expected to first expose more than 40 Aqara Zigbee devices ranging from smart sensors and wireless switches to controller-type devices such as radiator thermostats and curtain controllers*. Through the Aqara hubs, these devices will be able to support Matter and connect with other third-party Matter devices. Some of these devices are listed below:
- Door & Window Sensor
- Temperature & Humidity Sensor
- Motion Sensor and Motion Sensor P1
- Vibration Sensor
- Smart Wall Switch (US)
- Smart Wall Switch H1 EU
- Smart Plug (US & EU)
- Single Switch Module T1
- Wireless Mini Switch
- Wireless Remote Switch H1
- Wireless Remote Switch (Single & Double Rocker)
- Radiator Thermostat E1
- Roller Shade Driver E1
- Curtain Driver E1
- Roller Shade Controller (Zigbee 1.2)
- LED Bulb and LED Bulb T1 (Tunable White)
Aqara aims to provide a comprehensive suite of Matter-compatible devices to global users, and its Matter device portfolio will continue to grow and incorporate other existing Zigbee devices in the coming future. Ultimately more than 160 Aqara Zigbee products belonging to over 10 different device categories are expected to receive Matter support.
Moreover, a new lineup of Thread-based devices will be introduced. Building upon the success of Aqara’s iconic door and window sensor as well as the motion sensor, the Company will refresh the designs of these two devices to adopt the Thread protocol - among other enhancements - to allow for native Matter support and direct connection with Matter controllers. The new sensors, i.e. the Door and Window Sensor P2 and the Motion and Light Sensor P2, are set to release in early 2023. As part of the ongoing partnership between NXP Semiconductors and Aqara, the Aqara Thread sensor will be showcased at the NXP demo table on the Matter launch event in Amsterdam.
An array of Thread-based Aqara devices is to follow including various smart sensors, dimmer switches, smart plugs, lights, and the next-gen smart home hub with multi-protocol support. The Aqara Hub M3 is designed to not only allow Aqara Zigbee devices to support Matter, but also serve as a Thread Border Router and a Matter Controller and Commissioner, which can directly connect and manage Thread and Matter-compatible smart home devices. The Company also plans to open its Aqara Home app to support third-party Matter devices.
Aqara strives to offer high-quality, smart home solutions that are accessible to everyone, specifically focusing on creating a seamless user experience. The Matter standard undoubtedly raises connected home experiences to the next level with unprecedented interoperability and simplicity, and Aqara will continue to enrich its Matter portfolio to offer users even more options for their smart homes and to expedite the mass adoption of smart homes worldwide.
* A full list of the first Aqara Zigbee devices to receive Matter support is available here.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20221103005123/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
AI Meets Traditional Culture: Huangshan Captures Widespread Attention at ITB Berlin7.3.2026 10:22:00 CET | Press release
Huangshan, one of China’s most iconic scenic destinations, drew significant attention at this year’s ITB by presenting a compelling fusion of traditional Chinese culture and cutting-edge artificial intelligence under the slogan “The world of Huangshan is for the world.” This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260307909978/en/ International visitor admires Huangshan cultural and creative exhibits at the Huangshan stand during ITB Berlin. Located in eastern China’s Anhui Province, Huangshan is famed for its “Five Natural Wonders” — fantastic pines, grotesque rocks, sea of clouds, hot spring and winter snow. The mountain is widely regarded as one of China’s greatest mountain landscapes. It is also a rare natural heritage site that simultaneously holds multiple international designations, including UNESCO World Cultural and Natural Heritage status, a UNESCO Global Geopark and a World Biosphere Reserve. At ITB, the Huangsh
Incyte Announces the European Commission Approval of Zynyz® (retifanlimab) for the First-Line Treatment of Advanced Squamous Cell Carcinoma of the Anal Canal (SCAC)6.3.2026 22:42:00 CET | Press release
- Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (platinum-based chemotherapy) is the first systemic treatment for adult patients with advanced SCAC in Europe- The EC approval is based on results of the POD1UM-303 study which showed that adult patients with advanced SCAC achieved significantly improved progression-free survival with Zynyz in combination with carboplatin and paclitaxel as a first-line treatment compared to chemotherapy alone.1 Incyte (Nasdaq:INCY) today announced that the European Commission (EC) has approved Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (platinum-based chemotherapy) for the first-line treatment of adult patients with metastatic or with inoperable locally recurrent squamous cell carcinoma of the anal canal (SCAC). “The EC approval of Zynyz marks an important step forward for patients with advanced SCAC, a rare cancer for which meaningful treatment advances have not occurred in several decades,” said Bill Meur
Dfns Launches Payouts6.3.2026 21:27:00 CET | Press release
Dfns today announced the launch of Payouts, a new API enabling institutions to convert stablecoins to fiat and route payouts across multiple bank accounts while keeping wallet-level governance and controls in place. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260305327930/en/ Convert stablecoins to fiat and settle payouts to bank accounts in 94 countries, today. Solving the problem of single-rail off-ramps Today, most fintechs and institutions still hard-wire a single payout provider into their stack, or rely on vertically integrated models that bundle routing, pricing, custody, and settlement together. That approach may be convenient early on, but it creates structural problems at scale: weak price discovery because there is no competitive pressure on margins, limited auditability because routing decisions are opaque, and operational fragility because a single provider degradation in any corridor requires architectural i
Klarna Group Plc Clarifies Mechanics of March 9 Lock-Up Expiration6.3.2026 20:23:00 CET | Press release
Klarna Group plc (NYSE: KLAR) today issues the following clarification to ensure investors and market participants have accurate information regarding the mechanics of its lock-up expiration on March 9, 2026, the processes required before pre-IPO shares can be traded on the NYSE, and the prior liquidity opportunities already available to shareholders. This release contains only factual descriptions of the Company's share structure and applicable processes. It does not constitute guidance or a projection of any kind regarding future trading volumes, share price, or the intentions of any shareholder and speaks only as of the date of this press release. 1. 335 million locked-up shares — but two different categories Of the 378 million total ordinary shares outstanding, approximately 335 million are subject to lock-up restrictions expiring March 9, 2026. However, these shares fall into two distinct categories governed by separate sets of regulations. A. 159 million shares (48% of locked-up
Lone Star Funds Announces Agreement to Acquire the Capsules & Health Ingredients Division of Lonza Group AG6.3.2026 18:30:00 CET | Press release
Lone Star Funds (“Lone Star”) today announced that an affiliate of Lone Star Fund XII, L.P. has entered into a definitive agreement to acquire the Capsules & Health Ingredients (“CHI”) division of Lonza Group AG. As part of the transaction, Lonza will retain a 40% equity position in the business. Headquartered in Basel, Switzerland, CHI operates globally across the Americas, Europe and Asia Pacific. The business comprises three segments: Hard Empty Capsules: leading global manufacturer of gelatin and plant-based capsules offering a broad range of innovative solutions for pharmaceutical and nutraceutical customers. Dosage Form Solutions: end-to-end development and manufacturing platform serving nutraceutical and pharmaceutical customers. Health Ingredients: provider of branded, science-backed nutrition ingredients serving joint health, energy and active lifestyle markets. Lone Star believes CHI is a high-quality, globally recognized platform with strong technical capabilities, different
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom